Evidence map›Paper›PMID 42842595›Full record

ArticlePloS one2026

Burden and determinants of hyperglycaemia and dyslipidaemia in Zimbabwean adults living with HIV on dolutegravir-based first-line antiretroviral therapy: A cross-sectional study.

Ratidzo Chirimo, Danai Tavonga Zhou, Tinashe Mudzviti, Ian Machingura Ruredzo, Justen Manasa, Charles Chiedza Maponga, Zvenyika Alfred Reginald Gomo, Exnevia Gomo, Gene D Morse

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ratidzo ChirimoFaculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.ORCID https://orcid.org/0009-0006-9312-5700
Danai Tavonga ZhouFaculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
Tinashe MudzvitiFaculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.ORCID https://orcid.org/0000-0002-9817-7108
Ian Machingura RuredzoFaculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
Justen ManasaFaculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
Charles Chiedza MapongaFaculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
Zvenyika Alfred Reginald GomoFaculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
Exnevia GomoFaculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
Gene D MorseCentre for Integrated Global Biomedical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, Buffalo, New York, United States of America.

Funding

HIV Research Training ProgramD43TW010313 · FIC · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI Charles Enos Chiedza Maponga, Gene D. Morse · 2016 to 2026
$3.2M
FIC NIH HHS D43 TW010313Wellcome Trust
6 · The paper itself

Abstract

backgroundDolutegravir (DTG)-based antiretroviral therapy (ART) is now the preferred first-line regimen for people living with HIV (PLWH) globally, including in Zimbabwe, which has an estimated adult HIV prevalence of 12.9%. While DTG offers a high genetic barrier to resistance and favourable tolerability, it has been linked to metabolic abnormalities - including abdominal obesity, hypertension, dyslipidaemia, and impaired glucose regulation - that cluster together and increase the risk of cardiovascular disease and type 2 diabetes. Data on this burden remain limited in Zimbabwe. We conducted an exploratory, hypothesis-generating cross-sectional study to estimate the burden of hyperglycaemia and dyslipidaemia, and to identify their correlates, among PLWH on first-line DTG-based ART.

objectiveThis study aimed to determine the burden and correlates of hyperglycaemia and dyslipidaemia in Zimbabwean adults living with HIV on first-line DTG-based ART.

methodsA cross-sectional study was conducted from 20 January 2025-13 February 2025. The study participants were 171 PLWH receiving first-line DTG-based treatment at Parirenyatwa Group of Hospitals, in Harare, Zimbabwe. A structured questionnaire was administered to collect demographics, lifestyle information, clinical parameters and anthropometric indices. We calculated body mass index (BMI). Blood pressure measurements were taken with the participant in a resting position. Blood samples were collected and we measured HbA1c, glucose, total cholesterol (TC), HDL cholesterol (HDL-C), LDL cholesterol (LDL-C).

resultsOf the 171 participants, 67.8% were female, with a median age of 42.1 years (IQR 32.4-50.2). The majority had at least secondary education, and few were smokers (n = 9), while 23% reported alcohol use and 62.2% reported no regular exercise. Over half (57.9%) were overweight or obese, and 39.8% were hypertensive. The prevalence of dyslipidaemia and hyperglycaemia was 74.3% and 13.4%, respectively, with insulin resistance present in 56.1%. Non-ideal HDL-C was the most common lipid abnormality (50.5%), followed by raised LDL-C (33.3%), raised triglycerides (16%), and hypercholesterolaemia (10.3%). On multivariate analysis, increasing age was independently associated with hyperglycaemia (AOR 1.08, 95% CI 1.03-1.13, p = 0.002), while elevated blood pressure was independently associated with dyslipidaemia (AOR 2.64, 95% CI 1.03-6.78, p = 0.043).

conclusionDyslipidaemia and hyperglycaemia are highly prevalent among Zimbabwean adults on DTG-based ART, with elevated blood pressure and increasing age as key independent correlates. As this population ages on long-term ART, routine, integrated screening of BMI, blood pressure, glucose, and lipid profile is essential to mitigate cardiometabolic risk and sustain the success of DTG-based ART in Zimbabwe.

Indexed as

DyslipidemiasHeterocyclic Compounds, 3-RingHIV InfectionsHyperglycemiaOxazinesPiperazinesPyridonesAdultCross-Sectional StudiesDolutegravirFemaleHumansMaleMiddle AgedZimbabweDolutegravirHeterocyclic Compounds, 3-RingOxazinesPiperazinesPyridones

Identifiers

PMID42842595
PMCPMC13645037

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.